Posted On: 08/20/2015 12:00:49 AM
Post# of 30066
AGTC is at an early stage in their ophthalmology programs (RP, AMD, etc.) but this will give an idea of what it's worth even now.
AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed
AGTC has five ongoing ophthalmology development programs and proof-of-concept data in multiple indications.
AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed
Quote:
Under the terms of the agreements, Biogen will make near-term payments including an upfront payment in the amount of $124 million to AGTC, which includes a $30 million equity investment at a purchase price of $20.63 per share. AGTC is eligible to receive upfront and milestone payments exceeding $1 billion in total. Biogen will be granted a license to the XLRS and XLRP programs and the option to license discovery programs for three additional indications at the time of clinical candidate selection.
AGTC has five ongoing ophthalmology development programs and proof-of-concept data in multiple indications.
(0)
(0)
